A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
Abstract Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China. Methods The mNC regimen was administered to the e...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15011 |
| _version_ | 1797743836646080512 |
|---|---|
| author | Yue Chai Jiaxuan Liu Mingxia Jiang Maiyue He Zijing Wang Fei Ma Jiayu Wang Peng Yuan Yang Luo Binghe Xu Qiao Li |
| author_facet | Yue Chai Jiaxuan Liu Mingxia Jiang Maiyue He Zijing Wang Fei Ma Jiayu Wang Peng Yuan Yang Luo Binghe Xu Qiao Li |
| author_sort | Yue Chai |
| collection | DOAJ |
| description | Abstract Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China. Methods The mNC regimen was administered to the enrolled cases, including oral vinorelbine (VNR) 40 mg three times weekly (on days 1, 3 and 5 every week) and capecitabine (CAP) 500 mg three times a day, until disease progression or intolerable toxicity. The primary endpoint was the 1‐year progression‐free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR) and treatment‐related adverse events (TRAEs). Stratified factors included treatment lines and hormone receptor (HR) status. Results Between June 2018 and March 2023, 29 patients were enrolled into the study. The median follow‐up time was 25.4 months (range, 2.0–53.8). In the entire group, the 1‐year PFS rate was 54.1%. ORR, DCR and CBR were 31.0%, 96.6% and 62.1%, respectively. The mPFS was 12.5 months (range, 1.1–28.1). Subgroup analysis revealed that ORRs were 29.4% and 33.3% in first‐ and ≥second‐line chemotherapy, respectively. ORRs were 29.2% (7/24) and 40.0% (2/5) for HR‐positive MBC and metastatic triple‐negative breast cancer (mTNBC), respectively. Grade 3/4 TRAEs were neutropenia (10.3%) and nausea/vomiting (6.9%). Conclusions The dual oral mNC regimen showed very good safety features and improved compliance without loss of efficacy in both first‐ and second‐line treatments. The regimen also reached an excellent ORR in the mTNBC subgroup. |
| first_indexed | 2024-03-12T15:01:12Z |
| format | Article |
| id | doaj.art-248637297f8d443e881673fe2afe1409 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-12T15:01:12Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-248637297f8d443e881673fe2afe14092023-08-14T00:40:02ZengWileyThoracic Cancer1759-77061759-77142023-08-0114232259226810.1111/1759-7714.15011A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancerYue Chai0Jiaxuan Liu1Mingxia Jiang2Maiyue He3Zijing Wang4Fei Ma5Jiayu Wang6Peng Yuan7Yang Luo8Binghe Xu9Qiao Li10Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of VIP Medical Services National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Background This single‐arm prospective phase II trial was performed to assess the efficacy and safety of the dual oral metronomic vinorelbine and capecitabine (mNC) regimen in women with HER2‐negative metastatic breast cancer (MBC) in China. Methods The mNC regimen was administered to the enrolled cases, including oral vinorelbine (VNR) 40 mg three times weekly (on days 1, 3 and 5 every week) and capecitabine (CAP) 500 mg three times a day, until disease progression or intolerable toxicity. The primary endpoint was the 1‐year progression‐free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR) and treatment‐related adverse events (TRAEs). Stratified factors included treatment lines and hormone receptor (HR) status. Results Between June 2018 and March 2023, 29 patients were enrolled into the study. The median follow‐up time was 25.4 months (range, 2.0–53.8). In the entire group, the 1‐year PFS rate was 54.1%. ORR, DCR and CBR were 31.0%, 96.6% and 62.1%, respectively. The mPFS was 12.5 months (range, 1.1–28.1). Subgroup analysis revealed that ORRs were 29.4% and 33.3% in first‐ and ≥second‐line chemotherapy, respectively. ORRs were 29.2% (7/24) and 40.0% (2/5) for HR‐positive MBC and metastatic triple‐negative breast cancer (mTNBC), respectively. Grade 3/4 TRAEs were neutropenia (10.3%) and nausea/vomiting (6.9%). Conclusions The dual oral mNC regimen showed very good safety features and improved compliance without loss of efficacy in both first‐ and second‐line treatments. The regimen also reached an excellent ORR in the mTNBC subgroup.https://doi.org/10.1111/1759-7714.15011breast cancercapecitabinemetastasismetronomic chemotherapyvinorelbine |
| spellingShingle | Yue Chai Jiaxuan Liu Mingxia Jiang Maiyue He Zijing Wang Fei Ma Jiayu Wang Peng Yuan Yang Luo Binghe Xu Qiao Li A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer Thoracic Cancer breast cancer capecitabine metastasis metronomic chemotherapy vinorelbine |
| title | A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer |
| title_full | A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer |
| title_fullStr | A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer |
| title_full_unstemmed | A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer |
| title_short | A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer |
| title_sort | phase ii study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in chinese women with her2 negative metastatic breast cancer |
| topic | breast cancer capecitabine metastasis metronomic chemotherapy vinorelbine |
| url | https://doi.org/10.1111/1759-7714.15011 |
| work_keys_str_mv | AT yuechai aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT jiaxuanliu aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT mingxiajiang aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT maiyuehe aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT zijingwang aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT feima aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT jiayuwang aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT pengyuan aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT yangluo aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT binghexu aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT qiaoli aphaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT yuechai phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT jiaxuanliu phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT mingxiajiang phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT maiyuehe phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT zijingwang phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT feima phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT jiayuwang phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT pengyuan phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT yangluo phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT binghexu phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer AT qiaoli phaseiistudyofadoubletmetronomicchemotherapyregimenconsistingoforalvinorelbineandcapecitabineinchinesewomenwithher2negativemetastaticbreastcancer |